公开(公告)号：EP2850101A1

公开(公告)日：2015-03-25

申请号：EP13725298.7

申请日：2013-05-13

申请人： UCB Pharma, S.A.

发明人： FINNEY, Helene Margaret ,  LAWSON, Alastair David Griffiths ,  SHAW, Stevan Graham ,  SMITH, Bryan John ,  TYSON, Kerry Louise ,  KEVORKIAN, Lara ,  MEIER, Christoph ,  ATHERFOLD, Paul, Alan ,  SARKAR, Kaushik

IPC分类号： C07K16/28 ,  G01N33/53

CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K47/60 ,  A61K47/643 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5047 ,  G01N33/564 ,  G01N33/6854 ,  G01N33/6857 ,  G01N33/6893 ,  G01N2333/70535 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/104 ,  G01N2800/24 ,  G01N2800/28

摘要： The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

摘要翻译： 本公开涉及对FcRn特异性的抗体，包含其的制剂，治疗中的每一种的使用，用于表达和任选配制所述抗体的方法，编码抗体的DNA和包含所述DNA的宿主。

公开(公告)号：EP2125894A2

公开(公告)日：2009-12-02

申请号：EP08742182.2

申请日：2008-03-21

申请人： Biogen Idec MA, Inc. ,  UCB Pharma, S.A.

发明人： BURKLY, Linda C. ,  FERRANT-ORGETTAS, Janine L. ,  GARBER, Ellen A. ,  HSU, Yen-ming ,  SU, Lihe ,  TAYLOR, Frederick R. ,  ADAMS, Ralph ,  BROWN, Derek Thomas ,  POPPLEWELL, Andrew George ,  ROBINSON, Martyn Kim ,  SHOCK, Anthony ,  TYSON, Kerry Louise

IPC分类号： C07K16/28

CPC分类号： C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

摘要翻译： 本发明提供结合蛋白，包括抗体，抗体衍生物和抗体片段，并特异性结合CD154（CD40L）蛋白。 本发明因此提供了一个嵌合的，人源化或完全的人抗体，抗体衍生物或抗体片段在表位做特异性结合到其上的人源化Fab片段包括雅丁于SEQ ID NO的可变重链序列：1和包含可变轻链序列 根据SEQ ID NO：2特异性结合。 CD154结合本发明的蛋白可以引起相对于第二抗CD154抗体效应子功能降低。 本发明的CD154结合蛋白可用于诊断和治疗方法，：例如在治疗和预防疾病，包括涉及thosethat不希望的免疫应答通过做了CD154-CD40相互作用介导有用的。

公开(公告)号：EP2758432A1

公开(公告)日：2014-07-30

申请号：EP12761789.2

申请日：2012-09-10

申请人： UCB Pharma, S.A.

发明人： HUMPHREYS, David Paul ,  LIGHTWOOD, Daniel John ,  TYSON, Kerry Louise ,  KNIGHT, David Edward Ormonde ,  HERVÉ, Karine Jeannine Madeleine ,  COMPSON, Joanne Elizabeth ,  PAGE, Matthew Jon Timothy ,  PAYNE, Andrew Charles ,  FISHER, Nicola Louise ,  MACKENZIE, Brendon ,  COX, Matthew

IPC分类号： C07K16/12 ,  A61K39/40 ,  A61P31/04

CPC分类号： C07K16/1282 ,  A61K39/40 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/56911 ,  G01N33/573 ,  G01N33/6854 ,  G01N2333/91097

摘要： This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.

公开(公告)号：EP2545076A1

公开(公告)日：2013-01-16

申请号：EP11707186.0

申请日：2011-03-10

申请人： UCB Pharma S.A.

发明人： TYSON, Kerry Louise

IPC分类号： C07K16/28 ,  C07K16/46 ,  C12N15/13

CPC分类号： C07K14/70503 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/92

摘要： PD-1 antibody A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO : 1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO : 4 for CDR-L1, the sequence given in SEQ ID NO: 5 for CDR-L2 and the sequence given in SEQ ID NO : 7 for CDR-L3. The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.